Print Page  Close Window

Corporate Profile

Paratek is developing and commercializing innovative antibacterial therapeutics based upon tetracycline chemistry. Paratek has used its expertise in microbial biology and tetracycline chemistry to create chemically diverse and biologically distinct small molecules derived from the tetracycline class of molecules. Paratek’s two lead antibacterial product candidates are omadacycline and sarecycline. Omadacycline entered Phase 3 clinical development in June 2015. Sarecycline entered Phase 3 clinical development in December 2014.

Stock Information

PRTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$10.30
Change (%) Stock is Down 0.1 (0.96%)
Volume583,130
Data as of 05/25/18 4:00 p.m. ET

Latest News

05/22/18
Paratek Presents New Analysis Highlighting Efficacy of Omadacycline in Treating Community-Acquired Bacterial Pneumonia by Measures of Disease Severity
05/09/18
Paratek Pharmaceuticals Reports First Quarter 2018 Financial Results
05/01/18
Paratek Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04/25/18
Paratek Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
See More >>
Data provided by Nasdaq. Minimum 15 minutes delayed.